Clinical and demographic characteristics of the Graves’ disease patients and healthy controls.
| Demographic/clinical variable . | Graves’ disease n = 132 . | Healthy controls n = 140 . |
|---|---|---|
| Total number of hyperthyroid samplesa | 49 | 0b |
| Total number of euthyroid samplesa | 141 | 140b |
| Age (years): median (IQR) [range] | 46 (35-54) [20-92] | 51 (39-57) [20-70] |
| Female: n (%) | 111 (84%) | 87 (62%) |
| Smoking status (at time of ATD withdrawal)c | Unknown | |
| Current smoker | 15/65 (23%) | |
| Non-smoker | 50/65 (77%) | |
| Graves’ orbitopathy (at time of ATD withdrawal)c | Unknown | |
| Present | 9/65 (14%) | |
| Absent | 56/65 (86%) | |
| Thyroid function at time sample taken (hyperthyroid patients): median (IQR) [range] | (n = 49) | N/A |
| Free T4 (pmol/L) | 36 (27-52) [13-100] | |
| Free T3 (pmol/L) | 15.4 (9-26) [6.2-50] | |
| TRAb (IU/L) | 8.9 (4-29) [0-100] | |
| TPO Ab (IU/mL) | 34 (8-228) [0-600] | |
| Thyroid function at time sample taken (euthyroid patients): median (IQR) [range] | (n = 141) | N/A |
| Free T4 (pmol/L) | 16 (15-18) [10.8-21.7] | |
| Free T3 (pmol/L) | 4.7 (4.2-5.3) [3.8-5.8] | |
| TRAb (IU/L) | 0 (0-1.2) [0-85.9] | |
| TPO Ab (IU/mL) | 24 (12-79) [0-301] |
| Demographic/clinical variable . | Graves’ disease n = 132 . | Healthy controls n = 140 . |
|---|---|---|
| Total number of hyperthyroid samplesa | 49 | 0b |
| Total number of euthyroid samplesa | 141 | 140b |
| Age (years): median (IQR) [range] | 46 (35-54) [20-92] | 51 (39-57) [20-70] |
| Female: n (%) | 111 (84%) | 87 (62%) |
| Smoking status (at time of ATD withdrawal)c | Unknown | |
| Current smoker | 15/65 (23%) | |
| Non-smoker | 50/65 (77%) | |
| Graves’ orbitopathy (at time of ATD withdrawal)c | Unknown | |
| Present | 9/65 (14%) | |
| Absent | 56/65 (86%) | |
| Thyroid function at time sample taken (hyperthyroid patients): median (IQR) [range] | (n = 49) | N/A |
| Free T4 (pmol/L) | 36 (27-52) [13-100] | |
| Free T3 (pmol/L) | 15.4 (9-26) [6.2-50] | |
| TRAb (IU/L) | 8.9 (4-29) [0-100] | |
| TPO Ab (IU/mL) | 34 (8-228) [0-600] | |
| Thyroid function at time sample taken (euthyroid patients): median (IQR) [range] | (n = 141) | N/A |
| Free T4 (pmol/L) | 16 (15-18) [10.8-21.7] | |
| Free T3 (pmol/L) | 4.7 (4.2-5.3) [3.8-5.8] | |
| TRAb (IU/L) | 0 (0-1.2) [0-85.9] | |
| TPO Ab (IU/mL) | 24 (12-79) [0-301] |
See Figure S1 for further information about patient cohorts.
Abbreviations: N/A, not applicable; FT4, free thyroxine; FT3, free triiodothyronine; TRAb, thyroid stimulating hormone receptor autoantibody; TPO Ab, thyroid peroxidase antibody; ATD, antithyroid drug.
aIncludes the GD samples 6-10 weeks after ATD withdrawal (total number of GD samples studied = 190).
bPresumed normal thyroid function as all healthy control samples had no known medical history of thyroid disease.
cData available from 65/132 GD patients.
Clinical and demographic characteristics of the Graves’ disease patients and healthy controls.
| Demographic/clinical variable . | Graves’ disease n = 132 . | Healthy controls n = 140 . |
|---|---|---|
| Total number of hyperthyroid samplesa | 49 | 0b |
| Total number of euthyroid samplesa | 141 | 140b |
| Age (years): median (IQR) [range] | 46 (35-54) [20-92] | 51 (39-57) [20-70] |
| Female: n (%) | 111 (84%) | 87 (62%) |
| Smoking status (at time of ATD withdrawal)c | Unknown | |
| Current smoker | 15/65 (23%) | |
| Non-smoker | 50/65 (77%) | |
| Graves’ orbitopathy (at time of ATD withdrawal)c | Unknown | |
| Present | 9/65 (14%) | |
| Absent | 56/65 (86%) | |
| Thyroid function at time sample taken (hyperthyroid patients): median (IQR) [range] | (n = 49) | N/A |
| Free T4 (pmol/L) | 36 (27-52) [13-100] | |
| Free T3 (pmol/L) | 15.4 (9-26) [6.2-50] | |
| TRAb (IU/L) | 8.9 (4-29) [0-100] | |
| TPO Ab (IU/mL) | 34 (8-228) [0-600] | |
| Thyroid function at time sample taken (euthyroid patients): median (IQR) [range] | (n = 141) | N/A |
| Free T4 (pmol/L) | 16 (15-18) [10.8-21.7] | |
| Free T3 (pmol/L) | 4.7 (4.2-5.3) [3.8-5.8] | |
| TRAb (IU/L) | 0 (0-1.2) [0-85.9] | |
| TPO Ab (IU/mL) | 24 (12-79) [0-301] |
| Demographic/clinical variable . | Graves’ disease n = 132 . | Healthy controls n = 140 . |
|---|---|---|
| Total number of hyperthyroid samplesa | 49 | 0b |
| Total number of euthyroid samplesa | 141 | 140b |
| Age (years): median (IQR) [range] | 46 (35-54) [20-92] | 51 (39-57) [20-70] |
| Female: n (%) | 111 (84%) | 87 (62%) |
| Smoking status (at time of ATD withdrawal)c | Unknown | |
| Current smoker | 15/65 (23%) | |
| Non-smoker | 50/65 (77%) | |
| Graves’ orbitopathy (at time of ATD withdrawal)c | Unknown | |
| Present | 9/65 (14%) | |
| Absent | 56/65 (86%) | |
| Thyroid function at time sample taken (hyperthyroid patients): median (IQR) [range] | (n = 49) | N/A |
| Free T4 (pmol/L) | 36 (27-52) [13-100] | |
| Free T3 (pmol/L) | 15.4 (9-26) [6.2-50] | |
| TRAb (IU/L) | 8.9 (4-29) [0-100] | |
| TPO Ab (IU/mL) | 34 (8-228) [0-600] | |
| Thyroid function at time sample taken (euthyroid patients): median (IQR) [range] | (n = 141) | N/A |
| Free T4 (pmol/L) | 16 (15-18) [10.8-21.7] | |
| Free T3 (pmol/L) | 4.7 (4.2-5.3) [3.8-5.8] | |
| TRAb (IU/L) | 0 (0-1.2) [0-85.9] | |
| TPO Ab (IU/mL) | 24 (12-79) [0-301] |
See Figure S1 for further information about patient cohorts.
Abbreviations: N/A, not applicable; FT4, free thyroxine; FT3, free triiodothyronine; TRAb, thyroid stimulating hormone receptor autoantibody; TPO Ab, thyroid peroxidase antibody; ATD, antithyroid drug.
aIncludes the GD samples 6-10 weeks after ATD withdrawal (total number of GD samples studied = 190).
bPresumed normal thyroid function as all healthy control samples had no known medical history of thyroid disease.
cData available from 65/132 GD patients.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
